New insider activity at Medpace Holdings ( (MEDP) ) has taken place on November 25, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kevin M. Brady, the CFO and Treasurer of Medpace Holdings, has recently sold 3,000 shares of the company’s stock, amounting to a total transaction value of $1,771,050.
Recent Updates on MEDP stock
In recent developments, Medpace Holdings has been the focus of multiple clinical studies and collaborations, which have influenced analyst perspectives on its stock. BMO Capital initiated coverage with a Market Perform rating, citing the stock’s full valuation amid a challenging biotech funding environment and potential macroeconomic volatility. Medpace’s ongoing clinical studies, including the OPAL Study for lymphoid malignancies and collaborations with AVM Biotechnology and Telix Pharmaceuticals, highlight its strategic positioning in cancer and ARDS treatment research. These studies, particularly those targeting significant health conditions like ARDS and advanced cancers, could enhance investor confidence if successful, potentially driving positive stock performance. The company’s partnerships and focus on innovative therapies underscore its competitive stance in the healthcare sector.
Spark’s Take on MEDP Stock
According to Spark, TipRanks’ AI Analyst, MEDP is a Outperform.
Medpace Holdings demonstrates strong financial performance and positive earnings call sentiment, which are the most significant factors driving the score. Technical analysis indicates strong momentum but also suggests caution due to overbought conditions. The high P/E ratio impacts the valuation score, reflecting potential overvaluation concerns.
To see Spark’s full report on MEDP stock, click here.
More about Medpace Holdings
YTD Price Performance: 84.76%
Average Trading Volume: 312,611
Technical Sentiment Signal: Buy
Current Market Cap: $17.42B